You just read:

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

News provided by

Astellas Pharma Inc.

Feb 05, 2018, 17:10 ET